Moleculin Biotech Past Earnings Performance
Past criteria checks 0/6
Moleculin Biotech's earnings have been declining at an average annual rate of -19.1%, while the Biotechs industry saw earnings growing at 11.8% annually.
Key information
-19.1%
Earnings growth rate
24.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -124.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Moleculin Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -27 | 10 | 18 |
| 31 Dec 23 | 0 | -30 | 10 | 19 |
| 30 Sep 23 | 0 | -26 | 11 | 17 |
| 30 Jun 23 | 0 | -29 | 11 | 20 |
| 31 Mar 23 | 0 | -30 | 12 | 20 |
| 31 Dec 22 | 0 | -29 | 12 | 19 |
| 30 Sep 22 | 0 | -25 | 11 | 18 |
| 30 Jun 22 | 0 | -21 | 10 | 16 |
| 31 Mar 22 | 0 | -18 | 9 | 15 |
| 31 Dec 21 | 0 | -16 | 8 | 14 |
| 30 Sep 21 | 0 | -16 | 8 | 13 |
| 30 Jun 21 | 0 | -15 | 8 | 13 |
| 31 Mar 21 | 0 | -21 | 7 | 14 |
| 31 Dec 20 | 0 | -17 | 7 | 13 |
| 30 Sep 20 | 0 | -19 | 7 | 14 |
| 30 Jun 20 | 0 | -19 | 7 | 13 |
| 31 Mar 20 | 0 | -10 | 7 | 11 |
| 31 Dec 19 | 0 | -13 | 6 | 11 |
| 30 Sep 19 | 0 | -12 | 6 | 11 |
| 30 Jun 19 | 0 | -10 | 6 | 9 |
| 31 Mar 19 | 0 | -14 | 5 | 11 |
| 31 Dec 18 | 0 | -12 | 5 | 10 |
| 30 Sep 18 | 0 | -12 | 5 | 9 |
| 30 Jun 18 | 0 | -13 | 5 | 9 |
| 31 Mar 18 | 0 | -11 | 5 | 5 |
| 31 Dec 17 | 0 | -10 | 4 | 5 |
| 30 Sep 17 | 0 | -8 | 4 | 3 |
| 30 Jun 17 | 0 | -7 | 3 | 3 |
| 31 Mar 17 | 0 | -4 | 3 | 2 |
| 31 Dec 16 | 0 | -4 | 2 | 1 |
Quality Earnings: MOL is currently unprofitable.
Growing Profit Margin: MOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MOL is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare MOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: MOL has a negative Return on Equity (-124.26%), as it is currently unprofitable.